Skip to main content
. 2016 Mar 15;37(2):683–693. doi: 10.1177/0271678X16637880

Figure 2.

Figure 2.

Differences in PDRP and MSARP scores across diseases. (a) PDRP: One-way ANOVA showed significant effect of group (F(7,186)=46.651, p < 0.001). As expected, all LBD patients (PDND, PDD and DLB) showed significantly elevated PDRP scores compared to healthy control subjects (NL) (p < 0.021; post hoc Bonferroni). PDD and DLB patients showed greater PDRP scores compared to the PDND (p < 0.001; post hoc Bonferroni) although non-significant differences in UPDRS motor scores were observed across the groups (F(2, 43)=0.733, p = 0.486). Both MSA-P (p = 0.015; post hoc Bonferroni) and MSA-C (p < 0.001) patients showed significantly lower PDRP score which was in line with previous discrimination study11 while they are significantly different from each other (p = 0.002). However, both PSP and CBS patients were not significantly different from PDND (p = 1.0; post hoc Bonferroni). *Significantly different from NL (p < 0.05; post hoc Bonferroni test). $Significantly different from PDND (p < 0.05; post hoc Bonferroni test). (b) MSARP: One-way ANOVA showed significant effect of group (F(7,186)=19.865, p < 0.001). As expected, both MSA-P and MSA-C patients showed significantly elevated MSARP scores compared to NL (p < 0.001; post hoc Bonferroni). MSARP score was significantly lower in all LBD groups (p < 0.001; post hoc Bonferroni), but it was not significantly different from PSP (p = 1.0) and CBS (p = 0.745) compared to MSA-P. No significant difference was detected between MSA-P and MSA-C (p = 1.0; post hoc Bonferroni). *Significantly different from NL (p < 0.05; post hoc Bonferroni test). $Significantly different from MSA-P (p < 0.05; post hoc Bonferroni test).